Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
Poly(ADP-ribose)polymerase (PARP) inhibitors (PARPi) have recently been approved for the treatment of breast and ovarian tumors with defects in homologous recombination repair (HRR). Although it has been demonstrated that PARPi also sensitize HRR competent tumors to cytotoxic chemotherapies or radio...
| Published in: | Molecules |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-04-01
|
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/24/8/1559 |